SRB
Steve R. Bailey Portfolio
Invests via Frazier Life Sciences Management LP | Managed by James W. Brush, M.D.
Invests via Frazier Life Sciences Management LP
Managed by James W. Brush, M.D.
Automatically Tracked
Steve R. Bailey Profile
Steve R. Bailey has carved a significant niche within the financial services sector, establishing himself as a seasoned investor-operator with a robust background in corporate finance and venture capital. His diverse experience spans various industries, including technology and healthcare, where he has played key roles in scaling innovative startups into market leaders. Known for his strategic acumen and hands-on approach to growth, he effectively bridges the gap between entrepreneurial ambition and operational execution. His leadership not only reflects an understanding of dynamic market demands but also positions him as an influential figure capable of navigating complex investment landscapes.
Steve R. Bailey has carved a significant niche within the financial services sector, establishing himself as a seasoned investor-operator with a robust background in corporate finance and venture capital. His diverse experience spans various industries, including technology and healthcare, where he has played key roles in scaling innovative startups into market leaders. Known for his strategic acumen and hands-on approach to growth, he effectively bridges the gap between entrepreneurial ambition and operational execution. His leadership not only reflects an understanding of dynamic market demands but also positions him as an influential figure capable of navigating complex investment landscapes.
Investment Philosophy & Strategy
Analyzing emerging market trends reveals significant investment opportunities in innovative sectors. Steve R. Bailey leverages his extensive operational expertise to identify and support companies that exhibit strong growth potential and scalable business models. His approach often combines hands-on mentorship with strategic capital deployment, emphasizing long-term value creation over short-term gains. Through meticulous evaluation of entrepreneurial ventures, he focuses on fostering resilience and competitive advantage among startups within the technology and healthcare industries. This blend of financial insight and operational rigor positions him uniquely to not only drive successful investments but also contribute positively to the broader economic landscape.
Analyzing emerging market trends reveals significant investment opportunities in innovative sectors. Steve R. Bailey leverages his extensive operational expertise to identify and support companies that exhibit strong growth potential and scalable business models. His approach often combines hands-on mentorship with strategic capital deployment, emphasizing long-term value creation over short-term gains. Through meticulous evaluation of entrepreneurial ventures, he focuses on fostering resilience and competitive advantage among startups within the technology and healthcare industries. This blend of financial insight and operational rigor positions him uniquely to not only drive successful investments but also contribute positively to the broader economic landscape.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
364.24%
Gain +5.77%
Monthly
2.76%
Yearly
38.71%
Drawdown
52%
$3.63B
Equity
Holdings
$3.63B
Investment
$2.24B
$2.05B
Profit +$103.56M
Realized
$656.88M
Unrealized
$1.4B
Dividends
$0
Goals
Avg. 12.5% completed goals
Yearly
Gain > 5% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
5.77%
Profit
$103.56M
Win %
59%
This Week
Compared To Last Week
Gain
-3.25%
Profit
-$122.19M
Win %
59%
This Month
Compared to last month
Gain
-5.98%
Profit
-$231M
Win %
59%
This Year
Compared to last year
Gain
-14.93%
Profit
-$638.08M
Win %
65%
ARQT Arcutis Biotherapeutics Inc.
+8.94%
+$23.3M 
KLRA Kailera Therapeutics, Inc.
+6.26%
+$739,090 
EOLS Evolus Inc.
+5.68%
+$1.08M 
ZLAB Zai Lab Ltd.
+5.67%
+$2.43M 
LXEO Lexeo Therapeutics Inc.
+4.7%
+$596,336.01 
MAZE Maze Therapeutics Inc.
+4.1%
+$5.42M 
VOR Vor Biopharma Inc.
+3.89%
+$1.86M 
ALLO Allogene Therapeutics Inc.
+3.85%
+$1.12M 
MBX MBX Biosciences, Inc.
+3.67%
+$11.91M 
NAMS NewAmsterdam Pharma Co. N.V.
+3.52%
+$12.75M 
IMCR Immunocore Holdings plc American Depositary Receipt
+3.4%
+$467,814.63 
BBIO BridgeBio Pharma, Inc.
+3.12%
+$3.13M 
MIRM Mirum Pharmaceuticals Inc.
+3.01%
+$18.51M 
VALN Valneva SE
+3%
+$389,583.22 
IRON Disc Medicine Inc.
+2.92%
+$2.21M 
ACRS Aclaris Therapeutics, Inc.
+2.81%
+$467,910.53 
TARS Tarsus Pharmaceuticals Inc.
+2.75%
+$1.45M 
ALKS Alkermes plc
+2.46%
+$672,619.72 
AURA Aura Biosciences Inc.
+2.27%
+$994,000 
DSGN Design Therapeutics, Inc.
+2.26%
+$397,805.91 
STTK Shattuck Labs Inc.
+2.06%
+$412,500 
DYN Dyne Therapeutics Inc.
+2.06%
+$977,455.42 
ACAD Acadia Pharmaceuticals Inc.
+2.03%
+$560,897.22 
MNKD MannKind Corporation
+1.99%
+$396,000 
RLAY Relay Therapeutics Inc.
+1.76%
+$304,708.92 
PHAT Phathom Pharmaceuticals Inc.
+1.76%
+$1.62M 
PVLA Pavella Therapeutics Inc.
+1.58%
+$1.71M 
SVRA Savara Inc.
+1.58%
+$729,063.9 
KRYS Krystal Biotech Inc.
+1.57%
+$2.51M 
GLUE Monte Rosa Therapeutics, Inc.
+1.29%
+$127,100 
TRVI Trevi Therapeutics Inc.
+1.2%
+$1.44M 
AUTL Autolus Therapeutics plc American Depositary Receipt
+1.18%
+$88,958.2 
XLO Xilio Therapeutics, Inc.
+1.12%
+$42,250.5 
CYTK Cytokinetics, Incorporated
+1.1%
+$806,115.91 
ACHV Achieve Life Sciences Inc.
+1%
+$533,038.52 
ASND Ascendis Pharma A/S
+0.64%
+$325,348.97 
IBIO iBio, Inc.
+0.38%
+$5,860.4 
ERAS Erasca, Inc.
+0.27%
+$999,007.52 
PBLS Parabilis Medicines, Inc.
+0.24%
+$119,089.91 
BCRX BioCryst Pharmaceuticals Inc.
+0.06%
+$20,046.2 
NAMSW NewAmsterdam Pharma Company N.V.
-1.1%
-$60,039.96 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 421 | Longs Won 226/421 53% | Profit Factor 4.4 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $21.18M |
| Average Win $11.76M | Best Trade (Oct 15) $215.26M | Sharpe Ratio -46.19 |
| Average Loss -$3.09M | Worst Trade (Oct 14) -$37.65M | Z-Score -0.38 (29.5%) |
| Commissions $0 | Avg. Trade Length 1y 6m 2w 4d | Expectancy $4.88M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.02% |
| Consecutive Losing Trades | 1,174 | 1,056 | 939 | 822 | 704 | 587 | 469 | 352 | 235 | 117 |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| ACAD Acadia Pharmaceuticals Inc. | 1.44M | $34.49M | $28.25M | - | -$6.24M | -18.1% | +2.026% |
| ACHV Achieve Life Sciences Inc. | 7.61M | $49.72M | $53.84M | - | $4.11M | 8.27% | +1% |
| ACRS Aclaris Therapeutics, Inc. | 4.93M | $18.47M | $17.12M | - | -$1.35M | -7.33% | +2.811% |
| ALKS Alkermes plc | 700,647 | $19.88M | $28.05M | - | $8.18M | 41.13% | +2.456% |
| ALLO Allogene Therapeutics Inc. | 22.45M | $50.51M | $30.3M | - | -$20.21M | -40.01% | +3.846% |
| ARQT Arcutis Biotherapeutics Inc. | 9.87M | $182.96M | $284.09M | - | $101.13M | 55.28% | +8.936% |
| ASND Ascendis Pharma A/S | 225,155 | $44.4M | $51.44M | - | $7.04M | 15.85% | +0.637% |
| AURA Aura Biosciences Inc. | 7.1M | $46.35M | $44.8M | - | -$1.54M | -3.33% | +2.269% |
| AUTL Autolus Therapeutics plc American Depositary Receipt | 4.45M | $20.48M | $7.61M | - | -$12.88M | -62.87% | +1.183% |
| BBIO BridgeBio Pharma, Inc. | 1.55M | $44.81M | $103.67M | - | $58.86M | 131.34% | +3.118% |
| BCRX BioCryst Pharmaceuticals Inc. | 4.01M | $38.17M | $32.29M | - | -$5.87M | -15.39% | +0.062% |
| CYTK Cytokinetics, Incorporated | 1.16M | $54.43M | $74.38M | - | $19.94M | 36.64% | +1.096% |
| DSGN Design Therapeutics, Inc. | 1.81M | $25.77M | $18.01M | - | -$7.76M | -30.13% | +2.259% |
| DYN Dyne Therapeutics Inc. | 3.15M | $39.54M | $48.4M | - | $8.86M | 22.42% | +2.061% |
| EOLS Evolus Inc. | 2.63M | $23.63M | $20.07M | - | -$3.56M | -15.06% | +5.679% |
| ERAS Erasca, Inc. | 24.98M | $87.17M | $368.13M | - | $280.96M | 322.3% | +0.272% |
| GLUE Monte Rosa Therapeutics, Inc. | 1M | $16.45M | $9.97M | - | -$6.48M | -39.41% | +1.292% |
| IBIO iBio, Inc. | 1.95M | $3.77M | $1.53M | - | -$2.24M | -59.39% | +0.384% |
| IMCR Immunocore Holdings plc American Depositary Receipt | 484,782 | $15.03M | $14.21M | - | -$826,897.59 | -5.5% | +3.405% |
| IRON Disc Medicine Inc. | 1.35M | $64.4M | $77.73M | - | $13.33M | 20.7% | +2.924% |
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for Steve R. Bailey?
The largest contributions to the portfolio's profits come from the following stocks: BridgeBio Pharma, Inc - $130.07M, Alpine Immune Sciences Inc - $94.01M, Chinook Therapeutics, Inc - $91.87M, Rhythm Pharmaceuticals Inc - $71.74M, and Revolution Medicines Inc - $71.02M. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: AnaptysBio Inc - $26.18M, Rocket Pharmaceuticals Inc - $22.03M, AN2 Therapeutics, Inc - $19.35M, IVERIC bio Inc - $17.46M, and Bicycle Therapeutics plc American Depositary Receipt - $16.36M. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
How stable are Steve R. Bailey's monthly returns?
Steve R. Bailey's monthly returns look highly volatile. The portfolio shows large month-to-month swings, and the broader risk profile suggests that performance can change sharply over short periods. This kind of pattern may suit users who are comfortable with significant fluctuations, but it is less likely to appeal to those who prefer steadier and more predictable results.
Can Steve R. Bailey's strategy be considered aggressive or moderate?
Steve R. Bailey's strategy can be considered aggressive. The combination of high drawdowns, elevated volatility, and/or concentrated positions suggests a willingness to accept significant risk in pursuit of higher long-term returns. This approach is generally more suitable for users who are comfortable with large fluctuations in portfolio value.
Should beginners follow Steve R. Bailey's strategy?
Steve R. Bailey's strategy is unlikely to be suitable for beginners. The portfolio shows signs of high risk, significant volatility, or structural complexity, which can make it difficult to follow and potentially stressful for less experienced users. This type of approach is generally better suited to more advanced investors.
2026 © Marketlog. All Rights Reserved.
